L
Lihong Liu
Researcher at Aaron Diamond AIDS Research Center
Publications - 72
Citations - 8104
Lihong Liu is an academic researcher from Aaron Diamond AIDS Research Center. The author has contributed to research in topics: Antibody & Medicine. The author has an hindex of 18, co-authored 46 publications receiving 2822 citations. Previous affiliations of Lihong Liu include Columbia University & Chinese Academy of Sciences.
Papers
More filters
Journal ArticleDOI
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
TL;DR: In this paper, the authors show that B.1.7 is refractory to neutralization by most monoclonal antibodies against the N-terminal domain of the spike protein and is relatively resistant to a few monoclanal antibody against the receptor-binding domain.
Journal ArticleDOI
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Lihong Liu,Pengfei Wang,Manoj S. Nair,Jian Yu,Micah Rapp,Qian Wang,Yang Luo,Jasper Fuk-Woo Chan,Jasper Fuk-Woo Chan,Vincent Sahi,Amir Figueroa,Xinzheng V. Guo,Gabriele Cerutti,Jude Bimela,Jason Gorman,Tongqing Zhou,Zhiwei Chen,Zhiwei Chen,Kwok-Yung Yuen,Kwok-Yung Yuen,Peter D. Kwong,Peter D. Kwong,Joseph Sodroski,Michael T. Yin,Zizhang Sheng,Zizhang Sheng,Yaoxing Huang,Lawrence Shapiro,Lawrence Shapiro,David D. Ho +29 more
TL;DR: A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres, suggesting both of these regions at the top of the viral spike are immunogenic.
Posted ContentDOI
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
TL;DR: In this paper, the authors report that B.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of spike and relatively resistant to a number of mabs to the receptor-binding domain (RBD).
Journal ArticleDOI
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Sho Iketani,Lihong Liu,Yicheng Guo,Liyuan Liu,Jasper Fuk-Woo Chan,Yiming Huang,Maple Wang,Yang Luo,Jian Yu,Hin Chu,Kenn Ka-Heng Chik,Terrence Tsz-Tai Yuen,Michael T. Yin,Magdalena E. Sobieszczyk,Yaoxing Huang,Kwok-Yung Yuen,Harris H. Wang,Zizhang Sheng,David D. Ho +18 more
TL;DR: The identification of the Omicron (B.1.1) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 20211 immediately caused concern owing to the number of alterations in the spike glycoprotein that could lead to antibody evasion as discussed by the authors .
Posted ContentDOI
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
TL;DR: In this paper, the authors report that B.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of spike and relatively resistant to a few mabs to the receptor-binding domain (RBD).